What is the latest progress in the domestic launch of Belzutifan? Domestic market situation analysis

Belzutifan (Belzutifan) is an innovative targeted drug for the treatment of tumors related to hypoxia-inducible factor (HIF). Its main indications include solid tumors such as renal cell carcinoma related to von Hipper-Lindau syndrome (VHL). In recent years, with the continuous advancement of precision medicine, the drug has gradually been recognized by domestic and foreign drug regulatory agencies. At present, bestivan has been officially approved for marketing in my country, bringing new treatment options to relevant patients.

Although Bestifan is already on the market in China, it is not currently included in the national medical insurance directory, so patients still need to purchase it at their own expense when using the drug. Since this drug is an innovative targeted drug, its market price is relatively high. The specific drug purchase price will vary depending on the region and hospital channels. It is recommended that patients go to the local tertiary hospital pharmacy for consultation to obtain the most accurate price and supply information.

In contrast, the generic version of bezutivan produced in Laos through overseas channels has become an alternative choice for some patients. The price of this generic version is about more than 5,000 yuan, which is more economical than the price of domestic original drugs. According to the current public information, this version is highly consistent with the original drug in terms of drug ingredients, and some patients have reported that it has good clinical results, making it one of the most cost-effective options at present.

Generally speaking, besotivan is still in the early stages of promotion in the Chinese market, and it is not covered by medical insurance, which puts a heavy financial burden on some patients. In the future, as policy adjustments and market competition intensify, drug prices may become more rational. For patients in need of medication, it is recommended to weigh treatment options based on doctors’ opinions and pay attention to medical insurance policies and generic drug information to achieve a dual balance between efficacy and cost.

Reference materials:https://www.welireg.com/